Clinical trial NCT03831113
Conditions: Opiate Addiction Pregnancy
Keywords: Buprenorphine medication-assisted treatment (MAT) programs
Sponsor: Steve N. Caritis, MD
Start date: 2019-04-13; Completion date: 2022-12-22
Enrollment: 13 participants; Allocation: NON_RANDOMIZED; Intervention model: SEQUENTIAL

Brief summary:
This study is a pharmacodynamic study in pregnant women evaluating the relationship between buprenorphine concentration and outcome such as opioid withdrawal symptoms , NAS scores, neurodevelopmental and neuroanatomic outcomes. Strategies to reduce opioid exposure will be explored. There are 4 specific aims but only specific aim 4 is a clinical trial and reported here. In specific aim 4, eligible consenting women on buprenorphine in an MAT clinic will be assigned to 2 dose reduction regimens and their response to dose reduction will be measured using a visual analog scale.

Detailed description:
Opioid use has reached a staggering level and the associated deaths, neonatal consequences and economic impact are devastating. Buprenorphine and methadone are the two most commonly used medications for pregnant women in a Medication Assisted Treatment (MAT) program. Yet, the target concentration of these agents is not clearly identified. Furthermore, the relationship between drug exposure and adverse effects such as Neonatal Abstinence Syndrome and neurodevelopmental outcomes is unclear but contemporary thinking is that exposure (defined by maternal dose) is unrelated to adverse outcomes. The benefit of an MAT strategy is based on strong clinical data that demonstrates an improvement in perinatal outcomes in women participating in an MAT program. However, some women prefer to stop opioid medications entirely , but are not afforded this option in many MAT programs. The possibility that MAT is associated with some harms has received little attention but there are data that suggest that opioids adversely affect the fetal brain. If MAT is indeed associated with potential harms, then the option of Medically Supervised Withdrawal could be considered.

This study will assess two dose reduction strategies in a cohort of women who desire a reduction or elimination of their opioid exposure. The magnitude group will reduce the dose by either 1 or 2 mg weekly. The frequency group will reduce their dose by 2 mg alternately in one or 2 weeks

Arms: arm 1: Subjects will receive alternating reductions of 1 mg or 2 mg weekly. arm 2: Subjects will receive dose reductions of 2 mg on alternating intervals of 1 and 2 weeks.
Interventions: intervention 1: Magnitude Group intervention 2: Frequency Group
Intervention descriptions: intervention 1: Dose reductions will alternate between 1mg or 2 mg weekly until the subject is no longer taking buprenorphine or is at the lowest tolerable dose. intervention 2: Dose reductions of 2 mg will occur alternate between once weekly to biweekly until the subject is no longer taking buprenorphine or is at the lowest tolerable dose.

Protocol documents:
Prot_SAP_000.pdf: 
1 
 
5-24-2021 
 
 
Pharmacologically-based Strategies for Opioid Substitution Therapy During 
Pregnancy 
PRO18070495 / STUDY19100128 
NCT03831113 
Protocol version 1.8 
 
 
 
The Eunice Kennedy Shriver National Institute of Child Health and Human Development 
(NICHD) 
 
 
 
 
 
 
 
Principal Investigator: 
Steve N. Caritis, MD 
Magee-Womens Hospital 
300 Halket Street Room 2229 
Pittsburgh, PA 15213 
 
 


2 
 
 
Specific Aim 4 
Specific Aim 4 compares dose reduction strategies for Suboxone or Subutex in 
pregnancy that are based on the pharmacodynamic and pharmacokinetic 
characteristics of BUP. 
a) Primary Research Questions 
1. Is adherence during dose reduction influenced by the magnitude or frequency of a 
given dose reduction? 
2. Is adherence during dose reduction influenced by dosing frequency? 
3. Does mu receptor sensitivity change during dose reduction? 
 
b) Eligibility Criteria 
Inclusion Criteria – must meet all of the following: 
1. On a stable BID, TID or QID dosing regimen of BUP for at least 2 weeks as part of an 
established medication- assisted treatment (MAT) program. 
2. Willingness to undergo supervised dose reduction 
3. Subjects on BID, TID or QID dosing, willing to be assigned to the Magnitude, 
Frequency, or Dosing group, depending on their current dosing 
4. Single gestation between 14-30 weeks at the initiation of dose reduction 
5. On a BUP dose between 6- 24 mg daily (lower doses will not provide sufficient data 
points) 
6. Willingness to have urine samples tested for drugs of abuse and blood samples 
tested for BUP+M concentrations during the Medical Supervised Withdrawal (MSW) 
clinic appointments 
7. Willingness to attend weekly or biweekly MSW clinic appointments and to have daily 
contact via text messaging to complete daily logs of sleep quality, withdrawal 
symptoms and symptoms of craving. Subjects may consent to receiving daily text 
messages with a link to a REDCap where they can complete the daily questionnaires 
electronically. Alternatively, they may complete hard copies of the questionnaires and 
return them during their weekly clinic visits. 
8. Willingness to attend psychosocial support meetings, as needed. 
 
Exclusion criteria – cannot meet any of the following: 
1. Current use of cocaine, heroin, benzodiazepines, barbiturates, phencyclidine (PCP), 
or opioids other than BUP 
2. Currently taking more than two mental health medications 


3 
 
3. Active moderately severe depression (PHQ-9 score ≥15 or suicidal ideation) 
4. Current incarceration 
5. Lack of a phone or transportation to and from clinic. 
6. Major fetal malformation 
7. Mother with significant vaginal bleeding or serious medical or obstetrical complication 
that could adversely affect study 
8. Planned delivery at another institution 
9. HIV or AIDS 
10. Diagnosis of schizoaffective disorder or psychosis 
c) Pre-Study Screening 
The following information will be obtained for consented patients 1-2 weeks prior to 
initiation of the dose reduction: 
1. Demographic information: age, race, weight, height 
2. Medical history: medical disorders, mental health disorders 
3. Obstetrical history, including the outcome of all prior pregnancies 
4. Social history: alcohol, tobacco, and illicit drug use 
5. Depression Screening (Patient Health Questionnaire-2 (PHQ-2) and Patient Health 
Questionnaire-9 (PHQ-9), if necessary) 
6. Intake questionnaire 
7. Concomitant medications – Subjects who use withdrawal mitigating agents such as 
Benadryl or clonidine will not be excluded from the study. Research staff will track 
the use of all concomitant medications. 
8. Project gestational age and estimated date of delivery 
9. Vital signs: blood pressure, heart rate, respiratory rate 
10. Maternal blood work: BUN, creatinine, albumin, total protein, ALT, AST, BUP + M 
concentrations, maternal DNA for drug metabolizing enzymes, and PBMC analysis 
(Pitt site only), (the first sample for PBMC analysis may be drawn at any time during 
pregnancy) 
11. Urine sample will be collected and tested for the presence of drugs of abuse. 
12. Obtain routine medical record release forms and review procedures for the upcoming 
study visit. 
Notes: 
• 
BUN, creatinine, albumin, total protein, ALT, and AST will not be performed if results are 
available in the subject’s medical record as part of the standard of care during this pregnancy 
or if testing was performed during a previous Pre-Study Screening. 


4 
 
d) Study Design 
The pharmacologic properties of BUP that inform this specific aim include a long half-life that 
suggests that any dose reduction should not occur more often than every 5 days to allow the 
impact of that dose change to manifest. The long half-life also suggests that a higher reduction 
(i.e. 2 mg) will be well tolerated as the reduction in drug exposure (i.e. the reduction in 
plasma concentrations over time) will be gradual over the ensuing 5 days till a new steady 
state is reached. The third PK and PD characteristic of BUP is that plasma concentrations are 
better sustained above a specified critical value with more frequent dosing.51 Based on 
these pharmacologic characteristics of BUP, we will evaluate three strategies for supervised 
dose reduction. We will recruit 3 groups of pregnant women who are on a stable dose of 
BUP and are committed to supervised dose reduction. Recruitment will occur in our 
Pregnancy Recovery Center (PRC), from offices of other BUP writers, and from the 
Emergency Department (ED) at Magee. We will also enlist Dr. Craig Towers, MD at High 
Risk Obstetrical Consultants, in Knoxville, TN to assist in recruitment of eligible subjects at 
his institution for Specific Aim 4 only, pending IRB approval. Dr. Towers is an expert in dose 
reduction/detoxification during pregnancy and has published extensively on this topic. Dr. 
Towers will adhere to this multicenter protocol and Data Safety Monitoring Plan and report 
periodically to Dr. Caritis. 
At MWH, pregnant women with an opioid use disorder generally come for initiation of 
methadone or BUP as part of a MAT program. They often present to the ED and are told to 
contact the PRC if they wish to start BUP or they are admitted if experiencing withdrawal for 
transition to methadone. Those who prefer to initiate treatment with Suboxone or Subutex 
will be targeted for recruitment. Dr. Towers is a primary provider at High Risk Obstetrical 
Consultants for opioid dependent women and we structured our dose reduction strategy 
based on his experiences. 
Consenting subjects will be assessed for depression at the Pre-Study Screening. The Patient 
Health Questionnaire-2 (PHQ-2) will be administered as a screen for depression. If the PHQ-2 
score is 3 or greater, major depressive disorder is likely and subjects will be further evaluated 
with the Patient Health Questionnaire-9 (PHQ-9). The PHQ-9 is a multipurpose instrument for 
screening, diagnosing, monitoring and measuring the severity of depression. 


5 
 
• A PHQ-9 score of ≥ 15 represents moderately severe depression. Subjects with a score 
of ≥ 15 at the Pre-Study Screening will be excluded from participating in the study and 
will be referred to a mental health provider. 
Note: Question 9 on the PHQ-9 is a single screening question on suicide risk. If a subject 
answers yes to question 9, they are ineligible to continue with the study and will be 
immediately referred to a mental health provider for further assessment. 
Once recruited subjects are on a stable dose of Suboxone or Subutex for 2 or more 
weeks, we will initiate one of three dose reduction strategies. We will compare tolerance in 
the same person to an alternating 1 mg vs 2 mg weekly reduction (Magnitude group, n=10). 
In a second group (Frequency group, n=10) we will compare tolerance in the same person 
to an alternating 2 mg reduction occurring weekly vs bi-weekly. All subjects in the 
Magnitude and Frequency groups will be on TID or QID dosing. In a third group (Dosing 
Group, n=10) we will compare tolerance to either the Magnitude or Frequency reduction 
schedule in women who are on a BID dosing regimen. The comparisons in these three 
groups will address those fundamental questions required for development of a 
rational dose reduction strategy. Each of these strategies addresses a specific question 
about maternal accommodation to the specified dose change. The dose reduction 
magnitude of 1 mg vs 2 mg and the frequency of reduction of weekly vs bi-weekly 
selected are based in large part on the work of Sigmon et al.47 but larger and more 
frequent reductions could be considered. We chose this modest reduction strategy as we 
were concerned that more aggressive changes could lead to subject withdrawal and 
dissatisfaction. In the study of Sigmon et al.47, only 50% of participants were opioid 
abstinent with the 4-week taper (i.e.1.75 mg per week). We believe a slower taper 
regimen could improve upon this outcome. Table 1 provides an example of the dose 
reduction strategy assuming, as an example, a starting dose of 16 mg daily. Subjects on 
TID or QID dosing will be assigned to either the Frequency or Magnitude groups based on 
their current dosing. Subjects on BID dosing will be assigned to the Dosing group. 
• Subjects assigned to the Frequency group will have dose reductions of 2 mg on 
alternating intervals of 1 and 2 weeks. 
• Subjects assigned to the Magnitude group will have alternating reductions of 1 
then 2 mg every week. 


6 
 
• Subjects in the BID group will be assigned to the Dosing group. The Dosing 
group may follow the Magnitude (alternating 1 mg and 2 mg dose reductions 
weekly) or Frequency (2 mg dose reductions on alternating intervals of 1 and 2 
weeks) dose reduction schedules. 
In all groups, the alternating approach will continue until the subject is Suboxone or 
Subutex free or at the lowest dose tolerable. We appreciate that some subjects may not 
tolerate the recommended dose reduction especially at the lower doses. Subjects that 
experience withdrawal symptoms may be treated with ancillary medications such as 
Benadryl or clonidine. To minimize any risk of relapse, subjects who are intolerant to a 
given reduction will be allowed to go back to the last tolerated dose taken prior to the 
reduction. Visual Analog Scale (VAS) scoring will document their intolerance and this, 
combined with pharmacological data from the subject, will inform our development of an 
optimized pharmacological approach to dose reductions. After the subject has been on 
the higher dose for one week we will re-initiate the dose reduction strategy to which she 
was assigned. We will repeat this process one more time and if she remains intolerant to 
further dose reductions, we will not attempt further reductions but rather will maintain her 
on her current dose. If the subjects desires additional attempts at dose reduction, we will 
accommodate her request. At this time, she may elect to re-initiate the original dose 
reduction strategy or select an alternative reduction strategy. For all subjects, we will 
continue the surveillance approach we have in place throughout the pregnancy, delivery, 
and into the postpartum period. 
In all 3 groups, daily adherence, cravings and sleep measures will be compared 
within and across groups. During the Pre-Study Screening, we will explain the study to the 
subject and ask that she completes an Intake Questionnaire to better understand any 
previous experiences she may have had with opioid treatment or detox programs. We will 
also perform urine and blood testing to assure all entry criteria are fulfilled. 
Once 
consent is obtained, we will initiate a Suboxone or Subutex dose reduction schedule 
similar to the one shown in Table 1. To ascertain the impact of a dose change, all 
subjects will complete 4 daily VAS questionnaires similar to those used by Dunn et al. 46 
to assess withdrawal, cravings, sleep duration and sleep quality. The scales will range 
from a score of 0-10 for each question. Subjects that wish to be contacted via text will be 
sent a daily text with a link to the REDCap website where they can complete the VAS 


7 
 
questionnaire electronically throughout the dose reduction process. Subjects that are 
unable to receive daily text messages will be provided hard copies of the VAS 
questionnaire and instructed to return the completed forms to research staff at their next 
appointment. Clinic visits will occur weekly or biweekly at which time we will monitor 
plasma BUP+M, neurotransmitter and cotinine concentrations and perform a 
comprehensive urinary toxicology test. Additionally, at each clinic visit we will administer 
the Weekly Follow-up and Weekly Smoking and Alcohol Use questionnaires. We will also 
collect any completed VAS forms, if applicable, and perform COWS and Subjective 
Opioid Withdrawal Scale (SOWS) scores to assess current clinical and subjective 
symptoms of withdrawal and satiety. All subjects will receive psychosocial support, as 
needed. The timing of the subject’s scheduled visits will be determined by their healthcare 
provider. 
Since our focus is to assess whether the magnitude of the dose change, frequency of 
dose change and dosing frequency impact adherence during reduction, this 
pharmacodynamic study will be completed when the subjects are off BUP entirely or on 
the lowest tolerable dose. However, we will continue to see the subjects weekly or 
biweekly, monitor their adherence and continue to provide counseling sessions, as 
needed, until the 6-week postpartum visit. We will also evaluate peripheral blood 
mononuclear cells (PBMCs) as a surrogate marker of metabolic enzymes and 
transporters. The expression of drug metabolizing enzymes and transporters in the 
PBMCs will be correlated with the plasma concentrations of BUP and its major 
metabolites. Two maternal blood samples will be drawn for PBMC analysis; one during 
pregnancy and one in postpartum. The first sample will be drawn during the Pre-Study 
Screening; however, if this is not possible, it may be drawn at any time during pregnancy. 
The second sample will be drawn at 4-6 weeks postpartum, but as close as possible to the 
6-week postpartum visit. 
For subjects not enrolled in specific aim 3a or 3b, we will collect a cord blood sample at 
the time of delivery as well as maternal and newborn hair within 3 days of delivery, when 
possible. An additional cord blood sample (10 mL) will be drawn for genetic studies related 
to metabolizing enzymes, if the mother consents. The minimal amount of hair needed is 20 
mg but we will ask for 100 mg which is still a very small amount. Hair will be removed from 
the mothers and baby’s head (if consent is granted). Mother will decide where the hair will 


8 
 
be removed from her and her baby. The collection of these samples will be described in full 
detail during the consent process. 
Note: Subjects that consent to participate in specific aims 3 (Parts 1 or 2) will already have 
the cord blood and hair samples collected as part of that specific aim. The collection of these 
biological samples only applies to those subjects not already enrolled in specific aim 3. 
 
Table 1. 
 
Dose Reduction Schedules if Start Dose is 16 mg Daily 
Group 
Frequency 
Magnitude 
Dosing 
Strategy 
Reduce dose by 2 mg 
weekly then biweekly, 
repeat till dose=0 or at the 
lowest possible dose 
Reduce dose by 1 and 
then 2 mg weekly, repeat 
above till dose=0 or at the 
lowest possible dose 
May elect either the 
Frequency or Magnitude 
dose reduction schedule. 
Dosing 
Frequency 
QID or TID 
QID or TID 
BID 
Dose 
Week 1 
16 
16 
Refer to the appropriate 
dose schedule in the 
Frequency or Magnitude 
columns 
Week 2 
14 
15 
Week 3 
14 
13 
Week 4 
12 
12 
Week 5 
10 
10 
Week 6 
10 
9 
Week 7 
8 
7 
Week 8 
6 
6 
Week 9 
6 
4 
Week 10 
4 
3 
Week 11 
2 
1 
Week 12 
2 
0 
Week 13 
0 
0 
e) Statistics 
The outcome(s) of interest are the pharmacodynamic endpoints that reflect the 
acclimatization of the mu receptors and opioid-affected brain functions. Each subject in a 
group will undergo alternating treatments to minimize any between subject differences that 
would impact the response to the decrease in dose. In this study, we will rely on scores from 
the self-administered VAS questionnaires. We will determine both an average and highest 
value for each of the VAS questionnaires weekly. The average values over the 7 days of 


9 
 
that given dose from the VAS questionnaires will be combined to create a single score for 
each week. A similar approach will be taken for the highest rather than average values. 
Based on the study of Dunn et al 46,47, the mean value for the withdrawal VAS questionnaire 
(scale 1-10) in non-pregnant subjects was 30 with a standard deviation of ~25. These values 
are estimates since graphs were provided but not tabular data. A difference of 25% in the 
VAS combined scores between any of the comparisons would seem clinically meaningful. 
Thus, a sample size of 10 in each group is sufficient to detect a difference in VAS scores 
between any of the comparison groups. The comparisons in the Frequency group will be 
VAS scores between the 1 vs 2 week reductions. The comparisons in the Magnitude group 
would be VAS scores between the 1 and 2 mg reductions. The comparison in the Dose 
group will be a comparison of the VAS scores during the 1 mg and 2 mg reductions. Also, 
VAS scores in the Dose group will be compared to the VAS scores in the Magnitude group 
both at the 1 and 2 mg reductions. The change in mu receptor sensitivity will be 
determined by comparing the BUP+M 
concentration each week to the subjects VAS scores 
on craving and withdrawal symptoms. In women who 
supplement their weekly BUP regimen with other 
opioids detected at the weekly clinic visits 
their VAS questionnaires on withdrawal and craving 
will be scored as 100. Assay Methods: BUP+M will 
be assayed using UPLC-MS-MS. We have developed and validated this assay and with 
the new TQS system the LOQ is 15 ng/ml in plasma. BUP in hair and other tissues will be 
measured by modification of this method and incorporating elements of methods reported 
in the literature 30,31,33. Cotinine will be measured by minor modification of the published 
method 55. 
 
D. Study Procedures 
 
D.1 Screening for Eligibility 
The inclusion/exclusion criteria will be reviewed with the patient’s chart. Any woman who 
appears to be eligible will be informed about the study. If a patient appears to meet the 
criteria for enrollment and expresses interest in the study, she will be told about the study 
and asked to sign the informed consent form. She will be asked to sign a medical records 
Anticipated 
sum of 
mean VAS 
scores 
Percent 
Reduction in 
VAS scores 
Sample 
Size 
120 
0.15 
25 
120 
0.20 
15 
120 
0.25 
10 
120 
0.30 
7 


10 
 
release so that the medical records may be obtained. A copy of the signed consent form will 
be provided to the patient. 
D.1.i. Gestational Age Determination 
We will use the criteria recommended by the American Congress of Obstetricians and 
Gynecologists (ACOG). 
D.2 Informed Consent Procedures and Documentation 
 
Written informed consent will be obtained before entry into the trial. Full disclosure of the 
nature and potential risks of participating in the trial will be made. Women who are not 
fluent in English will be enrolled by a person fluent in their language and both verbal 
and written informed consent obtained in that language; if such are not available, they 
will not be included. 
D.3 Specimen Collection 
 
Per standard research procedures for Labor and Delivery samples, Magee Womens Hospital 
employs staff as part of the Obstetric Specimen Procurement Unit (OSPU), which is responsible 
for the collection of research study samples on the Labor and Delivery unit. Labor and Delivery 
samples will only be collected if possible. There is a 3-day window for collection of hair 
samples. Maternal and infant samples will be collected as shown in Table 2. 
D.4 Specimen Analysis and Collection of Negative Control Samples 
 
Biological specimens will be collected and labeled with the study and subject number only 
and stored in locked freezers at MWH or the Magee Women Research Institute or in the 
freezers at participating institutions. Only the study research staff will have access to 
individually identifiable private information. Biological specimens will intermittently be sent to 
Dr. Venkataramanan’s lab at the University of Pittsburgh for analysis. Samples sent for 
analysis will not contain any identifiable information. 
Negative Control Samples: Biological samples from women who are not taking BUP are 
required as negative controls. Subjects potentially eligible as negative controls will be 
identified by reviewing the medical records of patients presenting for prenatal or postpartum 
care at private offices or the MFM offices at MWH. Patients will be approached by their care 
provider or a co-investigator about the study. Healthy volunteers serving as negative controls 
will be recruited prior to delivery or within 6 weeks after delivery. Subjects recruited as 


11 
 
negative controls will be asked to sign a separate consent allowing for the collection of 
samples. 
The negative control samples will be collected during pregnancy, delivery or postpartum, as 
requested by Dr. Venkataramanan’s lab, and according to study procedures. The biological 
samples may include any of the following: placenta, umbilical cord blood, umbilical cord 
tissue, maternal hair, infant hair, and meconium. We will enroll up to 5 women for the 
collection of each sample type. 
D.4.i. Eligibility Criteria 
The following criteria apply to healthy volunteers serving as negative controls: 
Inclusion Criteria: 
1. Age between 18 – 45 years 
2. Current pregnancy or delivery within the last 6 weeks 
3. Able to give informed consent and undergo study procedures 
 
Exclusion Criteria: 
1. Currently taking buprenorphine 


12 
 
E. Feasibility: 
 
The sample size required in all 4 specific aims is small. Given the large opioid 
population in Pittsburgh (over 700 women with an opioid use disorder delivered at Magee 
between 2013-2015) and that number is increasing making completion of this study very 
feasible. Our MAT clinic sees 150 new patients annually and has received $500,000 from the 
state to increase its outreach efforts. I do not believe sample size will be an issue. 
Recruitment of subjects for specific aim 4, dose reduction may prove challenging since we 
have not offered this option previously at Magee; however, we performed a survey recently of 
potential candidates for dose reduction and detoxification and the response was very 
encouraging. Of 40 women asked if they would consider dose reduction or detoxification, more 
than 50% said they would be interested. Recruitment for specific Aim 1 may be challenging 
because the subject will need to be willing to allow withdrawal to occur in addition to 
spending time in the CRC. Time in the CRC has been an ongoing challenge to recruitment in 
all OPRU studies. Given that all the MAT clinic staff have been involved with our BUP 
research in the past and 2 BUP writers are supported by this grant, I am confident that we 
can recruit sufficient subjects to complete these aims. 
F. Potential Problems & Alternative Strategies 
 
For all specific aims, recruitment must be considered. Although this is unlikely to be 
problematic given our large population, it may be an issue. If recruitment is slower than 
required to achieve our goals, we will approach other research-oriented centers with a large 
opioid using population to assist in recruitment. 
For specific aim 4, possible problems include high drug withdrawal and craving on the 
lowest dose reduction and a high dropout rate. The possibility that even the lowest dose 
reduction will lead to unacceptable rates of dropout and study withdrawal rates is not likely 
given the reasonable dose reduction rates reported by others with dose reductions much 
greater than those proposed. If this does indeed happen then we would target an even 
slower rate of reduction. 
G. Subject Removal Criteria 


13 
 
For specific aim 4, if heroin, cocaine, benzodiazepines, barbiturates, phencyclidine 
(PCP), or opioids other than BUP are detected in the urine during the pre-study screening or at 
any time during the study, or if the urine drug screen results from the MAT clinic are positive at any 
time during her dose reduction, she will be dropped from the study and replaced. Subjects who 
do not return their residual drug on more than 3 occasions will be withdrawn from the study. 
H. 
Clinical Data Management 
Data from study participants will be collected on case report forms (CRFs) by research staff. 
These forms and all data relevant to the subjects and their babies will be kept in the subject’s 
research folder which will be kept under lock and key in the office of the study coordinator. All 
data will be entered into a research database which will be on a University of Pittsburgh 
secured and password protected server. 


14 
 
I. References 
1. Wilkerson RG, Kim HK, Windsor TA, Mareiniss DP. The Opioid Epidemic in the United 
States. Emerg Med Clin North Am. 2016 May;34(2):e1-e23. doi:10.1016/j.emc.2015.11.002. 
Epub 2016 Feb 17. Review. PMID:27133253. 
2. Brady KT, McCauley JL, Back SE. Prescription Opioid Misuse, Abuse, and Treatment 
in the United States: An Update. Am J Psychiatry. 2016 Jan;173(1):18 -26. doi: 
10.1176/appi.ajp.2015.15020262. Epub 2015 Sep4. Review. PMID: 26337039; PMCID: 
PMC4782928. 
3.  Soelberg CD, Brown RE Jr, Du Vivier D, Meyer JE, Ramachandran BK. The US Opioid 
Crisis: Current Federal and State Legal Issues. Anesth Analg. 2017 Nov;125(5):1675- 
1681.doi:10.1213/ANE.0000000000002403. Review. PMID:29049113. 
4. Murphy SM, Polsky D. Economic Evaluations of Opioid Use Disorder Interventions. 
Pharmacoeconomics. 2016 Sep;34(9):863-87. doi:10.1007/s40273-016-0400-5. Review. 
PMID:27002518; PMCID: PMC5572804. 
5.  
Clark DJ, Schumacher MA. America's Opioid Epidemic: Supply and Demand 
Considerations. 
Anesth 
Analg.2017 
Nov;125(5):1667-1674. 
doi:10.1213/ANE.0000000000002388. Review. PMID: 29049112. 
6. Clarke JL, Skoufalos A, Scranton R. The American Opioid Epidemic: Population Health 
Implications and Potential Solutions. Report from the National Stakeholder Panel. Popul 
Health Manag. 2016 Mar;19 Suppl1:S1-10. doi: 10.1089/pop.2015.0144. Review. PMID: 
26908092. 
7. Doberczak TM, Thornton JC, Bernstein J, Kandall SR. Impact of maternal drug dependency 
on birth weight and head circumference of offspring. Am J Dis Child. 1987 
Nov;141(11):1163-7. PMID: 3673965. 
8.  Finnegan LP, Reeser DS, Connaughton JF Jr. The effects of maternal drug dependence 
on neonatal mortality. Drug Alcohol Depend. 1977 Mar;2(2):131-40. PMID: 870299. 
9.  Hulse GK, Milne E, English DR, Holman CD. The relationship between maternal use of 
heroin and methadone and infant birth weight. Addiction. 1997 Nov;92(11):1571-9. PMID: 
9519499. 
10.  Minozzi S, Amato L, Bellisario C, Ferri M, Davoli M. Maintenance agonist treatments for 
opiate-dependent pregnant women. Cochrane Database Syst Rev. 2013 Dec 
23;(12):CD006318. doi: 10.1002/14651858. CD006318.pub3. Review. PMID:24366859. 
11.  Jones HE, Kaltenbach K, Heil SH, Stine SM, Coyle MG, Arria AM, O'Grady KE, Selby P, 
Martin PR, Fischer G. Neonatal abstinence syndrome after methadone or buprenorphine 
exposure. N Engl J Med. 2010 Dec 9;363(24):2320-31. doi: 10.1056/NEJMoa1005359. 
PMID: 21142534; PMCID: PMC3073631. 
12.  Jones HE, Heil SH, Baewert A, Arria AM, Kaltenbach K, Martin PR, Coyle MG, Selby P, 
Stine SM, Fischer G. Buprenorphine treatment of opioid-dependent pregnant women: a 
comprehensive review. Addiction. 2012 Nov;107 Suppl 1:5-27. doi: 10.1111/j.1360- 


15 
 
0443.2012.04035.x. Review. PMID: 23106923; PMCID: PMC4506646. 
13.  Substance Abuse and Mental Health Services Administration. Federal Guidelines for 
Opioid Treatment Programs. HHS Publication No (SMA)PEP15-FEDGUIDEOTP First 
Printed 2015. 
Rockville, MD: Substance Abuse and Mental Health Services 
Administration, 2015. 
14.  Center for Substance Abuse Treatment. Clinical Guidelines for the Use of Buprenorphine 
in the Treatment of Opioid Addiction. Treatment Improvement Protocol (TIP) Series 40. 
DHHS Publication No. (SMA) 05-4003. Rockville, MD: Substance Abuse & Mental Health 
Services Administration, 2005. 
15.  Bastian JR, Chen H, Zhang H, Rothenberger S, Tarter R, English D, Venkataramanan R, 
Caritis SN. Dose- adjusted plasma concentrations of sublingual buprenorphine are lower 
during than after pregnancy. Am J Obstet Gynecol. 2017 Jan;216(1):64.e1-64.e7. doi: 
10.1016/j.ajog.2016.09.095. Epub 2016 Sep 26. PMID:27687214; PMCID: PMC5245872. 
16.  Greenwald MK, Comer SD, Fiellin DA. Buprenorphine maintenance and mu-opioid 
receptor availability in the treatment of opioid use disorder: implications for clinical use 
and 
policy. 
Drug 
Alcohol 
Depend. 
2014 
Nov 
1;144:1-11. 
doi:10.1016/j.drugalcdep.2014.07.035. 
Epub 
2014 
Aug 
19. 
Review. 
PMID: 
25179217;PMCID: PMC4252738. 
17.  Greenwald M, Johanson CE, Bueller J, Chang Y, Moody DE, Kilbourn M, Koeppe 
R, Zubieta JK. Buprenorphine duration of action: mu-opioid receptor availability and 
pharmacokinetic and behavioral indices. Biol Psychiatry. 2007 Jan 1;61(1):101-10. Epub 
2006 Sep 1. PMID: 16950210. 
18.  Piva F, Limonta P, Dondi D, Pimpinelli F, Martini L, Maggi R. Effects of steroids on the brain 
opioid system. J Steroid Biochem Mol Biol. 1995 Jun;53(1-6):343-8. Review. PMID: 
7626478. 
19.  Sinchak K, Micevych PE. Progesterone blockade of estrogen activation of mu-opioid 
receptors regulates reproductive behavior. J Neurosci. 2001 Aug 1;21(15):5723-9. PMID: 
11466444. 
20.  Acosta-Martinez M, Etgen AM. Estrogen modulation of mu-opioid receptor-stimulated 
[35S]-GTP-gamma- 
S 
binding 
in 
female 
rat 
brain 
visualized 
by 
in 
vitro 
autoradiography. Neuroendocrinology. 2002 Oct;76(4):235-42. PMID: 12411740. 
21.  Peckham EM, Graves SM, Jutkiewicz E, Becker JB, Traynor JR. Role of gonadal hormones 
on mu-opioid- stimulated [³⁵S]GTPγS binding and morphine-mediated antinociception in male 
and female Sprague-Dawley rats. Psychopharmacology (Berl). 2011 Dec;218(3):483-92. 
doi: 10.1007/s00213-011-2335-z. Epub 2011 May 24. PMID: 21607564. 
22.  Finnegan LP, Connaughton JF Jr, Kron RE, Emich JP. Neonatal abstinence syndrome: 
assessment and management. Addict Dis. 1975;2(1-2):141-58. PMID:1163358. 
23.  McQueen K, Murphy-Oikonen J. Neonatal Abstinence Syndrome. N Engl J 
Med. 2016 Dec 22;375(25):2468-2479. doi: 10.1056/NEJMra1600879. Review. PMID: 
28002715. 
24.  Kraft WK, Dysart K, Greenspan JS, Gibson E, Kaltenbach K, Ehrlich ME. Revised dose 
schema of sublingual buprenorphine in the treatment of the neonatal opioid abstinence 
syndrome. Addiction. 2011 Mar;106(3):574-80. doi:10.1111/j.1360-0443.2010.03170.x. 


16 
 
Epub 2010 Oct 6. PMID: 20925688; PMCID:PMC3022999. 
25.  Grossman MR, Berkwitt AK, Osborn RR, Xu Y, Esserman DA, Shapiro ED, Bizzarro MJ. 
An Initiative to Improve the Quality of Care of Infants With Neonatal Abstinence Syndrome. 
Pediatrics. 2017 Jun;139(6). pii: e20163360. doi:10.1542/peds.2016-3360. Epub 2017 May 
18.PMID: 28562267; PMCID: PMC5470506. 
26.  Caritis SN, Panigrahy A. Opioids affect the fetal brain: reframing the detoxification debate. 
Am J Obstet Gynecol. 2019 Dec;221(6):602-608. doi:10.1016/j.ajog.2019.07.022. Epub 
2019 Jul 16. PMID: 31323217. 
27.Ng CM, Dombrowsky E, Lin H, Erlich ME, Moody DE, Barrett JS, Kraft WK. Population 
Pharmacokinetic 
Model 
of 
Sublingual 
Buprenorphine 
in 
Neonatal 
Abstinence 
Syndrome. Pharmacotherapy. 2015 Jul;35(7):670-80. doi: 10.1002/phar.1610. Epub 2015 
Jul 14. PMID: 26172282; PMCID: PMC5119858. 
28. O'Connor AB, O'Brien L, Alto WA. Maternal Buprenorphine Dose at Delivery and Its 
Relationship 
to 
Neonatal 
Outcomes. 
Eur 
Addict 
Res. 
2016;22(3):127-30. 
doi:10.1159/000441220. Epub 2015 Oct 23. PMID:26491960. 
29. Kacinko SL, Jones HE, Johnson RE, Choo RE, Huestis MA. Correlations of maternal 
buprenorphine dose, buprenorphine, and metabolite concentrations in meconium with 
neonatal  outcomes.  Clin  Pharmacol  Ther.  2008 
Nov;84(5):604-12. 
doi:10.1038/clpt.2008.156. 
Epub 
2008 
Aug 
13. 
PMID: 
18701886; 
PMCID:PMC2714885. 
30.  Shah D, Brown S, Hagemeier N, Zheng S, Kyle A, Pryor J, Dankhara N, Singh P. 
Predictors of neonatal abstinence syndrome in buprenorphine exposed newborn: can cord 
blood buprenorphine metabolite levels help? Springerplus. 2016 Jun 23;5(1):854. doi: 
10.1186/s40064-016-2576-8. eCollection 2016. PMID:27386303; PMCID: PMC4919189. 
31.  Jones HE, Dengler E, Garrison A, O'Grady KE, Seashore C, Horton E, Andringa K, 
Jansson LM, Thorp J. Neonatal outcomes and their relationship to maternal buprenorphine 
dose during pregnancy. Drug Alcohol Depend. 2014 Jan 1;134:414-417. doi: 
10.1016/j.drugalcdep.2013.11.006. Epub 2013 Nov 16. PMID:24290979; PMCID: 
PMC4117648. 
32.  Concheiro M, Jones HE, Johnson RE, Choo R, Shakleya DM, Huestis MA. Umbilical cord 
monitoring of in utero drug exposure to buprenorphine and correlation with maternal dose 
and neonatal outcomes. J Anal Toxicol. 2010 Oct;34(8):498-505. PMID: 21819795. 
33.  Concheiro M, Jones HE, Johnson RE, Choo R, Shakleya DM, Huestis MA. Maternal 
buprenorphine dose, placenta buprenorphine, and metabolite concentrations and 
neonatal 
outcomes. 
Ther 
Drug 
Monit. 
2010 
Apr;32(2):206-15. 
doi:10.1097/FTD.0b013e3181d0bd68. PMID: 20216119; PMCID: PMC2921577. 
34.  Kacinko SL, Jones HE, Johnson RE, Choo RE, Huestis MA. Correlations of maternal 
buprenorphine dose, buprenorphine, and metabolite concentrations in meconium with 
neonatal 
outcomes. 
Clin 
Pharmacol 
Ther.2008 
Nov;84(5):604-12. 
doi:10.1038/clpt.2008.156. 
Epub 
2008 
Aug 
13. 
MID: 
18701886; 
PMCID: 
PMC2714885. 
35.  Pirro V, Fusari I, Di Corcia D, Gerace E, De Vivo E, Salomone A, Vincenti M. Hair analysis 
for long-term monitoring of buprenorphine intake in opiate withdrawal. Ther Drug Monit. 
2014 Dec;36(6):796-807. doi:10.1097/FTD.0000000000000078. PMID: 24713865. 


17 
 
36.  Belivanis S, Tzatzarakis MN, Vakonaki E, Kovatsi L, Mantsi M, Alegakis A, Kavvalakis 
MP, Vynias D, Tsatsakis AM. Buprenorphine and nor-buprenorphine levels in head hair 
samples from former heroin users under Suboxone® treatment. Drug Test Anal. 2014 Jun;6 
Suppl 1:93-100. doi: 10.1002/dta.1611. PMID:24817054. 
37.  Goodwin RS, Wilkins DG, Averin O, Choo RE, Schroeder JR, Jasinski DR, Johnson RE, 
Jones HE, Huestis MA. Buprenorphine and norbuprenorphine in hair of pregnant women 
and their infants after controlled buprenorphine administration. Clin Chem. 2007 
Dec;53(12):2136-43. Epub 2007 Oct 5. PMID: 17921260. 
38.  Skopp G, Kniest A, Haisser J, Mann K, Hermann D. Buprenorphine and norbuprenorphine 
findings in hair during constant maintenance dosage. Int J Legal Med. 2011 
Mar;125(2):277-81. doi: 10.1007/s00414-011-0555-8. Epub 2011 Feb 8. PMID: 21301858. 
39.  Wilkins DG, Rollins DE, Valdez AS, Mizuno A, Krueger GG, Cone EJ. A 
retrospective study of buprenorphine and norbuprenorphine in human hair after 
multiple doses. J Anal Toxicol. 1999 Oct;23(6):409-15. PMID: 10517544. 
40.  Zuspan FP, Gumpel JA, Mejia-Zelaya A, Madden J, Davis R. Fetal stress from methadone 
withdrawal. Am J Obstet Gynecol. 1975 May 1;122(1):43-6. PMID:1130446. 
41.  Stewart RD, Nelson DB, Adhikari EH, McIntire DD, Roberts SW, Dashe JS, Sheffield JS. 
The obstetrical and neonatal impact of maternal opioid detoxification in pregnancy. 
Am J Obstet Gynecol. 2013 Sep;209(3):267.e1-5. doi:10.1016/j.ajog.2013.05.026. Epub 
2013 May 29. PMID: 23727040. 
42.  Jones HE, O'Grady KE, Malfi D, Tuten M. Methadone maintenance vs. methadone taper 
during pregnancy:maternal  and  neonatal  outcomes.  Am  J  Addict.  2008 
Sep-Oct;17(5):372-86. doi:10.1080/10550490802266276. PMID: 18770079. 
43.  Bell J, Towers CV, Hennessy MD, Heitzman C, Smith B, Chattin K. Detoxification from 
opiate drugs during pregnancy. Am J Obstet Gynecol. 2016 Sep;215(3):374.e1-6. doi: 
10.1016 /j.ajog.2016.03.015. Epub 2016 Mar 17. PMID: 26996987. 
44.  Stewart RD, Nelson DB, Adhikari EH, McIntire DD, Roberts SW, Dashe JS, Sheffield JS. 
The obstetrical and neonatal impact of maternal opioid detoxification in pregnancy. 
Am J Obstet Gynecol. 2013 Sep;209(3):267.e1-5. doi: 10.1016/j.ajog.2013.05.026. Epub 
2013 May 29. d PMID: 23727040. 
45.  Dunn KE, Saulsgiver KA, Miller ME, Nuzzo PA, Sigmon SC. Characterizing opioid withdrawal 
during double- blind  buprenorphine  detoxification.  Drug  Alcohol  Depend.  2015 
Jun 1;151:47-55.  doi:10.1016/j.drugalcdep.2015.02.033. Epub 2015 Mar 12.  PMID: 
25823907; PMCID: PMC4447545. 
46.  Sigmon SC, Dunn KE, Saulsgiver K, Patrick ME, Badger GJ, Heil SH, Brooklyn JR, 
Higgins ST. A randomized, double-blind evaluation of buprenorphine taper duration in 
primary prescription opioid abusers. JAMA Psychiatry. 2013 Dec;70(12):1347-54. doi: 
10.1001/jamapsychiatry.2013.2216. PMID: 24153411; PMCID: PMC4131728. 
47.  Koob GF, Volkow ND. Neurobiology of addiction: a neurocircuitry analysis. Lancet 
Psychiatry. 2016 Aug;3(8):760-73. doi: 10.1016/S2215-0366(16)00104-8. Review. 
PubMed PMID: 27475769. 
48. Kosten TR, George TP. The neurobiology of opioid dependence: implications for 
treatment. Sci Pract Perspect. 2002 Jul;1(1):13-20. Review. PMID: 18567959; PMCID: 


18 
 
PMC2851054. 
49.  Peters J, De Vries TJ. Glutamate mechanisms underlying opiate memories. Cold Spring 
Harb Perspect Med. 2012 Sep 1;2(9):a012088. doi:10.1101/cshperspect.a012088. 
Review. PMID: 22951449; PMCID: PMC3426813. 
50.  Caritis SN, Bastian JR, Zhang H, Kalluri H, English D, England M, Bobby S, 
Venkataramanan R. An evidence-based recommendation to increase the dosing frequency 
of buprenorphine during pregnancy. Am J Obstet Gynecol. 2017 Oct;217(4):459.e1-459.e6. 
doi: 10.1016/ j.ajog.2017. 06.029. Epub 2017 Jun 29. PMID: 28669739; PMCID: 
PMC5614874 
51. Kalluri HV, Zhang H, Caritis SN, Venkataramanan R. A physiologically based 
pharmacokinetic modelling approach to predict buprenorphine pharmacokinetics following 
intravenous and sublingual administration. Br J Clin Pharmacol. 2017 Nov;83(11):2458- 
2473. doi: 10.1111/bcp.13368. Epub 2017 Aug 22. PMID:28688108; PMCID: 
PMC5651326. 
52.  Pichini S, Garcia-Algar O. In utero exposure to smoking and newborn neurobehavior: 
how to assess neonatal withdrawal syndrome? Ther Drug Monit. 2006 Jun;28(3):288-90. 
PMID: 16778707. 
53. Wikner BN, Stiller CO, Bergman U, Asker C, Källén B. Use of benzodiazepines and 
benzodiazepine receptor agonists during pregnancy: neonatal outcome and congenital 
malformations. Pharmacoepidemiol Drug Saf. 2007 Nov;16(11):1203-10 PMID: 17894421. 
54. Gentile S. On categorizing gestational, birth, and neonatal complications following late 
pregnancy exposure to antidepressants: the prenatal antidepressant exposure syndrome. 
CNS Spectr. 2010 Mar;15(3):167-85. Review. PMID: 20414166 
55.  Liachenko N, Boulamery A, Simon N. Nicotine and metabolites determination inhuman 
plasma by ultra performance liquid chromatography-tandem mass spectrometry:a simple 
approach for solving contamination problem and clinical application.Fundam Clin 
Pharmacol. 2015 Oct;29(5):499-509. doi:10.1111/fcp.12132. Epub 2015 Aug 11. PubMed 
PMID: 26118829. 
56.  Lemon LS, Caritis SN, Venkataramanan R, Platt RW, Bodnar LM. Methadone versus 
buprenorphine for opioid use dependence and risk of neonatal abstinence syndrome. 
Epidemiology. 2017 Nov 6. doi:10.1097/EDE.0000000000000780. [Epub ahead of print] 
PMID: 29112519. 
57.  Serra AE, Lemon LS, Mokhtari NB, Parks WT, Catov JM, Venkataramanan R, Caritis SN. 
Delayed villous maturation in term placentas exposed to opioid maintenance therapy: a 
retrospective cohort study. Am J Obstet Gynecol. 2017 Apr;216(4):418.e1-418.e5. doi: 
10.1016/j.ajog.2016.12.016. Epub 2016 Dec 23. PMID: 28024 
58.  Debelak K, Morrone WR, O'Grady KE, Jones HE. Buprenorphine + naloxone in the 
treatment of opioid dependence during pregnancy-initial patient care and outcome data. 
Am J Addict. 2013 May-Jun;22(3):252-4. doi:10.1111/j.1521-0391.2012.12005.x. PubMed 
PMID: 23617867. 
59.  Dooley J, Gerber-Finn L, Antone I, Guilfoyle J, Blakelock B, Balfour-Boehm J, Hopman 
WM, Jumah N, Kelly L. Buprenorphine-naloxone use in pregnancy for treatment of opioid 
dependence. Can Fam Physician 2016;62:e194-200. 


19 
 
60. Jumah NA, Edwards C, Balfour-Boehm J, Loewen K, Dooley J, Gerber Finn L, Kelly 
L. Observational study of the safety of buprenorphine+naloxone in pregnancy in a rural 
and remote population. BMJ Open 2016;6:e011774. doi:10.1136/bmjopen-2016-011774. 
61.  Wiegand SL, Stringer EM, Stuebe AM, Jones H, Seashore C, Thorp J. Buprenorphine and 
naloxone compared with methadone treatment in pregnancy. Obstet Gynecol. 2015 
Feb;125(2):363-8. doi: 10.1097/AOG.0000000000000640. PubMed PMID:25569005. 
62.  Lund IO, Fischer G, Welle-Strand GK, O'Grady KE, Debelak K, Morrone WR, Jones HE. 
A Comparison of Buprenorphine + Naloxone to Buprenorphine and Methadone in the 
Treatment of Opioid Dependence during Pregnancy: Maternal and Neonatal Outcomes. 
Subst Abuse. 2013;7:61-74. doi: 10.4137/SART.S10955. Epub 2013 Mar 14. PubMed 
PMID: 23531704; PubMed Central PMCID: PMC3603528. 
63.  British Columbia Centre on Substance Use, B.C. Ministry of Health, B.C. Ministry of Mental 
Health and Addictions, & Perinatal Services BC. A Guideline for the Clinical Management 
of Opioid Use Disorder—Pregnancy Supplement. Published June 1, 2018. Available at: 
http://www.bccsu.ca/care-guidance-publications.